Navigation Links
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Date:4/29/2009

ths of treatment. At the end of the initial 6 months, all patients will be dosed on a PRN (as needed) basis for another 6 months. All patients will be eligible for rescue laser treatment.

About VEGF Trap-Eye

Vascular Endothelial Growth Factor (VEGF) is a naturally occurring protein in the body whose normal role is to trigger formation of new blood vessels (angiogenesis) to support the growth of the body's tissues and organs. It has also been associated with the abnormal growth and fragility of new blood vessels in the eye and vascular permeability and edema. VEGF Trap-Eye is a fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF). Investigational VEGF Trap-Eye is a specific blocker of VEGF-A and PlGF that has been demonstrated in preclinical models to bind these growth factors with greater affinity than their natural receptors.

Regeneron and Bayer HealthCare are collaborating on the global development of VEGF Trap-Eye for the treatment of wet AMD, DME, CRVO, and other eye diseases and disorders. Bayer HealthCare will market VEGF Trap-Eye outside the United States, where the companies will share equally in profits from any future sales of VEGF Trap-Eye. Regeneron maintains exclusive rights to VEGF Trap-Eye in the United States.

About Regeneron Pharmaceuticals

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain and has preclinical programs in other diseases and disorders. Additional information about Regeneron and recent news releases are
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.; Bayer HealthCare AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
2. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
3. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
4. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
5. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
6. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
7. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
8. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
9. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
10. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
11. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Company (NYSE: PRGO ; TASE) today announced ... from the U.S. Food and Drug Administration (FDA) for ... gel 1.0%. FDA concluded that Perrigo,s testosterone product is ... substituted with the full expectation that it will produce ... 1% when used under the conditions specified in the ...
(Date:7/24/2014)... , July 24, 2014 Research ... "Machine Health Monitoring Market by Product, Component, Application and ... report to their offering. ... market is expected to witness a moderate growth as ... have almost reached the saturation levels. The ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- Delivery ... once order is placed. Photo - ... a professional and in-depth market survey on Global ... reviews the basic information of Hemodialysis Machine including ... then explores global and China,s top manufacturers of ...
Breaking Medicine Technology:Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5
... Dec. 8, 2010 Reportlinker.com announces that a ... catalogue: Astellas Pharma Inc.: PharmaVitae ... IntroductionThis analysis examines the historical ... pharmaceutical sector. The profile encompasses global company strategy, ...
... 8, 2010 Healthpoint today announced that the U.S. ... commercial supplies of Collagenase SANTYL® Ointment, a biologic enzymatic ... Sterile & Specialty Products facility in Lakewood, New Jersey. ... the brand. "The approval of this second ...
Cached Medicine Technology:Reportlinker Adds Astellas Pharma Inc.: PharmaVitae Profile 2FDA Approves New Manufacturing Facility for Collagenase SANTYL® Ointment 2
(Date:7/24/2014)... Doheny HealthDay Reporter THURSDAY, ... often don,t view their kids as unhealthy or recognize the ... new study. The children of the families surveyed for ... Hasbro Children,s Hospital in Providence, R.I. "A third categorized ... researcher Dr. Kyung Rhee, now an assistant professor of pediatrics ...
(Date:7/24/2014)... have found a way to delay or even prevent ... with the anti-aging protein Klotho can prevent neuron death ... glutamate. These findings currently appear in the Journal ... the most frequent age-related dementia affecting 5.4 million Americans ... and more than 40 percent of people over the ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 News ... that it has achieved certification for compliance with ... and verified by the DoD Information Assurance Certification ... Neutral Archive, identified within the DoD as the ... to Operate designation from the U.S. Army Medical ...
(Date:7/24/2014)... positive outcomes experience paradoxical feelings of pleasure and ... of the brain, according to research led by ... Princeton Neuroscience Institute at Princeton University. , ... of more than 300 products using an auction-like ... products with different or similar values and were ...
(Date:7/24/2014)... 24, 2014 Horizon BCBSNJ’s second annual ... lucky family a rent-free week in a beautiful Lavallette ... 2014. Don’t miss your chance to win a week’s ... to all New Jersey residents, 25 or older.* Residents ... http://www.facebook.com/HorizonBCBSNJ . , “A family vacation at ...
Breaking Medicine News(10 mins):Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2
... LDG ) today reported preliminary total retail drug,store sales for the five-week and nine-week periods ended April 3, 2008., , ... Periods ended April 3, 2008, ... Month Quarter to Date (Dollars in millions) ... (9 weeks), Total retail drug store sales $474 ...
... IRIDEX,Corporation (Nasdaq: IRIX ) today reported final financial results ... Revenue for the fourth quarter of 2007 was $14.1 ... fourth quarter of 2006. The,Company,s net loss was $15.8 million ... compared with a loss of $3.8 million or $0.48 per,diluted ...
... consequences of misuse , , THURSDAY, April 10 (HealthDay News) ... abuse of powerful narcotic painkillers such as Oxycontin or ... testing --- before dispensing the medications to patients, new ... medical staff were also part of the procedures used ...
... Pennsylvania School of Medicine have discovered that a protein ... heart muscle protein called actin. Whats more, Lmod directs ... of the heart. The findings appear in this weeks ... Lmod when we began this study, says lead author ...
... Methodist Healthcare -- Memphis,Hospitals ("Methodist") announced today that it ... maturities of the,Bonds. The tender offer was extended on ... 9, 2008 at 5:00 pm, New York City time. ... terminated is applicable to,the following: for the Series 1985C ...
... Held on Saturday, April 12th at the ... Helen Mills Theatre in NYC, NEW ... performing a benefit concert on Saturday,April 12th at the Helen Mills Theatre ... This One,s Personal: A,Concert to Stop ACD," is being hosted by the ...
Cached Medicine News:Health News:Longs Reports Preliminary March Retail Drug Store Sales 2Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 7Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 8Health News:User Registry May Help Docs Stem Painkiller Abuse 2Health News:Penn researchers discover 'modus operandi' of heart muscle protein 2Health News:Methodist Healthcare - Memphis Hospitals Announces Termination of Tender Offers 2Health News:Kristin Chenoweth to Perform Benefit Concert for 3 Angels Memorial Fund titled, 'Kristin Chenoweth, This One's Personal: A Concert to Stop ACD' 2Health News:Kristin Chenoweth to Perform Benefit Concert for 3 Angels Memorial Fund titled, 'Kristin Chenoweth, This One's Personal: A Concert to Stop ACD' 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: